Q BioMed is focused on accelerating the development of innovative biomedical technologies, particularly in the biotechnology and healthcare sectors. The company aims to create a diverse pipeline of biomedical assets across various therapeutic areas, emphasizing the importance of minimizing risks and maximizing returns. Their strategy includes acquiring and financing undervalued biomedical assets, which allows them to support companies in transitioning from early-stage development to commercialization. Q BioMed leverages its expertise in business and product development, along with a network of strategic partners, to provide public market access for private company assets, addressing the common challenge of capital shortages faced by many biomedical startups.

One of the key products in Q BioMed's pipeline is Strontium-89, a radiopharmaceutical used for the palliative treatment of bone pain associated with metastatic cancer. Clinical studies have demonstrated its effectiveness in providing significant pain relief for patients suffering from cancer-induced bone pain, with many experiencing improved pain control after a single injection. Strontium-89 can be redosed every 90 days, and Q BioMed is actively pursuing full regulatory and marketing approval for this treatment in major markets worldwide. The company has also initiated a Named Patient Program to ensure immediate global access to Strontium-89, reflecting its commitment to patient-centered care and the management of bone metastases.

United States

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Q BioMed

Company Details